{"id":8511,"date":"2025-09-05T19:38:02","date_gmt":"2025-09-05T16:38:02","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=8511"},"modified":"2025-09-05T19:38:02","modified_gmt":"2025-09-05T16:38:02","slug":"myosin-inhibitors-in-hypertrophic-cardiomyopathy-hcm-esc-2025","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/myosin-inhibitors-in-hypertrophic-cardiomyopathy-hcm-esc-2025\/","title":{"rendered":"Myosin Inhibitors in Hypertrophic Cardiomyopathy (HCM) \u2013 ESC 2025"},"content":{"rendered":"<div>Myosin Inhibitors in Hypertrophic Cardiomyopathy (HCM) \u2013 ESC 2025<\/div>\n<div><\/div>\n<div>Source: Medical News | ESC 2025 | August 30, 2025<\/div>\n<div><\/div>\n<div><span> 1. Background<\/span><\/div>\n<div><span> \u2022 Myosin inhibitors (aficamten, mavacamten) target excessive contractility in HCM.<\/span><\/div>\n<div><span> \u2022 Current guidelines: beta-blockers are first-line for obstructive HCM; no approved therapies for non-obstructive HCM.<\/span><\/div>\n<div><span> 2. MAPLE-HCM (Phase 3, obstructive HCM)<\/span><\/div>\n<div><span> \u2022 Design: 175 symptomatic patients, LVEF \u226560%, randomized to aficamten vs metoprolol.<\/span><\/div>\n<div><span> \u2022 Primary endpoint: Change in peak VO\u2082.<\/span><\/div>\n<div><span> \u2022 Results:<\/span><\/div>\n<div><span> \u2022 +2.3 mL\/kg\/min improvement with aficamten vs decline with beta-blockers (P&lt;.001).<\/span><\/div>\n<div><span> \u2022 Significant improvements in: NYHA functional class, KCCQ score, NT-proBNP, and LVOT gradient.<\/span><\/div>\n<div><span> \u2022 Benefits consistent across all subgroups.<\/span><\/div>\n<div><span> \u2022 Implication: First controlled evidence that a myosin inhibitor is superior to beta-blockers as first-line therapy \u2192 may change guidelines if approved.<\/span><\/div>\n<div><span> 3. ODYSSEY-HCM (Phase 3, non-obstructive HCM)<\/span><\/div>\n<div><span> \u2022 Design: 289 patients, randomized mavacamten vs placebo, 48 weeks.<\/span><\/div>\n<div><span> \u2022 Results:<\/span><\/div>\n<div><span> \u2022 Primary endpoints (peak VO\u2082, KCCQ score) not met (P=0.07 and 0.06).<\/span><\/div>\n<div><span> \u2022 NT-proBNP reduced and small improvements in NYHA class observed, but nonsignificant.<\/span><\/div>\n<div><span> \u2022 Higher treatment interruption due to AEs in the mavacamten group (14.6% vs 5.2%).<\/span><\/div>\n<div><span> \u2022 Implication: No proven benefit for mavacamten in non-obstructive HCM; disease remains a major unmet need.<\/span><\/div>\n<div><span> 4. Overall Takeaways<\/span><\/div>\n<div><span> \u2022 Aficamten: Positive, may shift first-line therapy for obstructive HCM ahead of beta-blockers.<\/span><\/div>\n<div><span> \u2022 Mavacamten: Failed in non-obstructive HCM despite prior promise; further studies needed.<\/span><\/div>\n<div><span> \u2022 Guideline impact: ESC experts suggested MAPLE-HCM results could lead to revised treatment sequence for obstructive HCM.<\/span><\/div>\n<div><\/div>\n<div><a href=\"http:\/\/www.medscape.com\/viewarticle\/new-trials-clarify-role-myosin-inhibitors-hypertrophic-2025a1000myv\">http:\/\/www.medscape.com\/viewarticle\/new-trials-clarify-role-myosin-inhibitors-hypertrophic-2025a1000myv<\/a><\/div>\n<div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Myosin Inhibitors in Hypertrophic Cardiomyopathy (HCM) \u2013 ESC 2025 Source: Medical News | ESC 2025 | August 30, 2025 1. Background \u2022 Myosin inhibitors (aficamten, mavacamten) target excessive contractility in HCM. \u2022 Current guidelines: beta-blockers are first-line for obstructive HCM; no approved therapies for non-obstructive HCM. 2. MAPLE-HCM (Phase 3, obstructive HCM) \u2022 Design: 175 [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8511","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8511","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=8511"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8511\/revisions"}],"predecessor-version":[{"id":8512,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8511\/revisions\/8512"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=8511"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=8511"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=8511"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}